Several other AR signaling inhibitors (ARSI) used in high-risk patients with localized PCa in combination with ADT include non-steroidal anti-androgens such as flutamide, bicalutamide, and nilutamide, and AR inhibitors such as enzalutamide, apalutamide, and darolutamide that directly interact with the AR-LBD to ultimately reduce AR-mediated signaling [1,6,15,16]. Here, AR is linked to posterior cortical atrophy.